1. Scrip
  2. >>Business

Watch This Space: Glenmark-SaNOtize’s COVID-19 Nasal Spray Debuts In India

 
• By Anju Ghangurde

Glenmark's partnered nitric oxide nasal spray for COVID-19 debuts in India at about $11, with the firm spotlighting the reduction in viral load with the product and potential to cut the chain of transmission. But more competition appears to be in the wings.

herd immunity
Can Glenmark's partnered nitric oxide nasal spray gain traction? • Source: Alamy

Canada-based biotech firm SaNOtize Research and Development Corporation’s novel Nitric Oxide Nasal Spray (NONS) for COVID-19 has hit the Indian market, with the firm seemingly eyeing opportunities in other parts of Asia as well, including Japan.

The India launch comes after local partner Glenmark Pharmaceuticals Limited received a go-ahead for the product (branded FabiSpray) from the Indian

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

More from Scrip

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.